


PRODUCT INFORMATION



Benserazide (hydrochloride)

Item No. 20298

CAS Registry No.: 14919-77-8
Formal Name: 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide-serine, monohydrochloride
Synonym: Ro 4-4602
MF: C₁₀H₁₅N₃O₅ • HCl
FW: 293.7
Purity: ≥95%
UV/Vis.: λ_{max}: 338 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Benserazide (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the benserazide (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Benserazide (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of benserazide (hydrochloride) in these solvents is approximately 16 and 20 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of benserazide (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of benserazide (hydrochloride) in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Benserazide is a peripherally restricted inhibitor of aromatic L-amino acid decarboxylase (AADC; IC₅₀ = 0.53 μM).¹ It also inhibits tryptophan oxygenase and kynureninase (K_is = 41.8 and 26.4 μM, respectively, in rat liver homogenates), as well as hexokinase 2 (HK2), HK1, and HK4 (IC₅₀s = 5.5, 25.1, and 40.5 μM, respectively, for the recombinant human enzymes).^{2,3} Benserazide (50-400 μM) is cytotoxic to SW480 colorectal cancer cells, an effect that can be reversed by HK2 siRNA knockdown, and inhibits proliferation of SW480, LoVo, HCT116, MCF-7, and SMMC-7721 cancer cells with IC₅₀ values of 143, 151, 181.4, 186, and 210.4 nM, respectively.³ It reduces tumor growth in an SW480 mouse xenograft model when administered at doses of 300 and 600 mg/kg per day for 16 days. Benserazide (10 and 50 mg/kg) inhibits striatal AADC and enhances L-DOPA-induced increases in striatal dopamine levels in a mouse model of Parkinson's disease induced by 6-OHDA (Item No. 25330).⁴

References

- Schultz, E. *Biomed. Chromatogr.* **4**(6), 242-244 (1990).
- Bender, D.A. *Biochem. Pharmacol.* **29**(5), 707-712 (1980).
- Li, W., Zheng, M., Wu, S., et al. *J. Exp. Clin. Cancer Res.* **36**(1), 58 (2017).
- Shen, H., Kannari, K., Yamato, H., et al. *Tohoku J. Exp. Med.* **199**(3), 149-159 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM